1. 831PClinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis. (23rd October 2018) Authors: Tauber, R L; Knorr, K; Schwaiger, S; Retz, M; Maurer, T; D'Alessandria, C; Wester, H-J; Gschwend, J; Weber, W; Schwaiger, M; Heck, M M; Eiber, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (19th November 2019) Authors: Horwich, A; Babjuk, M; Bellmunt, J; Bruins, H M; Reijke, T M De; Santis, M De; Gillessen, S; James, N; Maclennan, S; Palou, J; Powles, T; Ribal, M J; Shariat, S F; Kwast, T Van Der; Xylinas, E; Agarwal, N; Arends, T; Bamias, A; Birtle, A; Black, P C Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗